Journal of the American Geriatrics Society
Fecha de publicación: 2 August 2017
DOI: 10.1111/jgs.14997
Autores: James E. Galvin MD, MPH
Abstract: Alzheimer’s disease (AD) affects more than 5 million Americans, with substantial consequences for individuals with AD, families, and society in terms of morbidity, mortality, and healthcare costs. With disease-modifying treatment trials unsuccessful at the present time and only medications to treat symptoms available, an emerging approach is prevention. Advances in diagnostic criteria, biomarker development, and greater understanding of the biophysiological basis of AD make these initiatives feasible.
